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Introduction
Recently there has been renewed interest in the detection
and treatment of hypercholesterolaemia; these being of
particular importance in young and middle-aged patients
with myocardial infarction [1]. It has lately been shown
that, contrary to existing dogma, measurement ofserum
or plasma cholesterol levels within the first 24 h after
infarction is a reliable way to assess prognosis or advise
treatment [2]. Moreover, ifresults ofcholesterol analyses
were available without undue delay while the patient was
still hospitalized in the short-stay coronary care unit, the
treatment would be initiated by the specialist cardiologist
and the required screening of first-degree relatives
visiting the patient might be easier to motivate.
One approach to providing results in a timely manner is
to perform analyses closer to the patient [3]. Although
cholesterol analyses have been performed in an out-
patient clinic [4], there does not appear to be data on the
provision of such assays in a coronary care unit. The
Ames Seralyzer is a system, based upon reflectance
spectroscopy and use of solid-phase reagents, which has
been stated to be convenient and reliable [5], although
not without problems and difficulties [7 and 8]. Little
data are available on the performance of cholesterol
assays and the system was therefore subjected to a full
evaluation in the laboratory under optimal conditions
variance [9], and to a trial in the coronary care unit
operated by threejunior medical staff. Current criteria for
acceptability ofperformance characteristics were applied
to data assessment.
aliquot (30 1) to the strip. Enzymatic hydrolysis of
cholesterol esters and oxidation of cholesterol produces
peroxide which is measured by the oxidative coupling of
3-methyl-2-benzothiazolinone and primaquine disphos-
phate, in the presence of peroxidase, to produce a
red-coloured complex. Incubation is timed automatically
(135 s) and results are displayed digitally to one decimal
place in mmol/1 units.
Imprecision
Within-run imprecision was assessed by analysis of three
sera from patients, 20 times each, following calibration of
the analyser. Between-run imprecision was assessed by
analysis of thawed frozen portions of the same three sera
20 times in separate analytical runs; calibration was
performed before each run, when a new bottle of test
strips was used, or if CAL appeared on the instrument
display panel. The results are shown in table 1.
Linearity
A pool of patient’s specimens with high levels of
cholesterol was generated and two series of six samples
made by dilution of aliquots of this pool with both water
and portions of a pool of patient’s specimens with low
levels of cholesterol. All samples were analysed in
duplicate in separate analytical runs. Using the criterion
that the found value should lie within:
2 SD between-run the ideal + V’ No. ofreplicates
then the analyses were statistically linear up to at least
11.0 mmol/1.
The Ames Seralyzer and reagent test strips were kindly
provided by the manufacturer for the purposes of this
study.
Methods and results
The instrument
The Ames Seralyzer is based upon reflectance spectro-
scopy and solid phase reagent strips, bar-coded for the
analyte. Calibrators at two levels are supplied. Analysis
requires separation of serum followed by a nine-fold
aqueous dilution step and application of a measured
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Comparative inaccuracy
100 Specimens from patients were analysed on the
Seralyzer and on a Rotochem IIa parallel fast analyser
(Aminco, Silver Spring, Massachusetts, USA), using
CHOD/PAP enzymatic end-point colorimetric method-
ology standardized with Precilip EL material (both from
Boehringer Mannheim, Mannheim, FR Germany). The
relationship between the results is shown in figure 1;
statistical analysis, as advocated by Westgard and Hunt
[10], gave a correlation coefficient of 0"980 and the
relationship"
Seralyzer 0"97 comparative method + 0.05.
The mean of the results obtained on the Seralyzer was
6"85 mmol/l and the mean by the comparative method
was 7"00 mmol/1, which, by the Wilcoxon matched pairs
signed rank test, was significantly higher (p >0"001).
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Table 1. Within-run and between run imprecision.
Level Within-run Between-run
N Mean (mmol/1) SD (mmol/l) CV(%) N Mean (mmol/l) SD (mmol/l) CV(%)
Low 20 3"4
Medium 20 6"7
High 20 9.8
0.18 5"3 20 3.3 0"25 7"8
0.19 2"8 20 6"5 0.17 2"6
0"28 2"9 20 9"8 0.34 3.5
Cholesterol
(retool/I)
[Seralyzer]
12
10
r= 0.98
y 0.97x + 0.05
0 2 4 6 8 10 12
Cholesterol (rnmol/I) [Rotochem Ila]
Figure 1. Comparison of cholesterol results on 100 patients"
specimens assayed by the Seralyzer in the laboratory and by the
laboratory.
Table 2. Analysis ofmaterials with assigned values.
Material
Assigned value Allowable error
(mmol/1) (mmol/l)
Value found
(mmol/1)
6.14 +0.19 6.50
2 2"99 _+0.29 3.10
3 4"49 +0.19 4.50
4 8.17 +_0"39 8"37
5 5"43 +0"19 5"70
6 2-73 +_0"29 2.73
7 4"14 +_0"19 4"17
8 6"23 +_0.19 6.70
9 8.17 +0.39 8"53
Analysis ofmaterials with assigned values
Three samples from an external quality assurance
scheme (UK NEQUAS, Birmingham, UK), three sam-
ples assayed by a number of laboratories to assist a
manufacturer to assign values to a product, and three
samples with assigned values obtained from the Lipid
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Standardization Laboratory (Centers for Disease Con-
trol, Atlanta, Georgia, USA), were analysed in triplicate
in separate analytical batches. The results are shown in
table 2, together with the acceptable error, this being
defined as:
2 SD between-run + X/ No. ofreplicates
Interference
The effect of lipaemia was investigated by duplicate
analyses of six samples generated by mixing portions ofa
lipaemic specimen with aliquots of a non-lipaemic
specimen. The effect of icterus was determined in a
similar manner using an icteric and non-icteric specimen.
The effect of haemolysis was investigated, firstly by
duplicate analyses of six samples produced by mixing
portions of a specimen to which a small amount of an
erythrocyte haemolysate had been added to give a
haemoglobin of 5.3 g/1 with portions ofanother specimen
and, secondly by duplicate analysis of aliquots of a series
offive samples which were produced by addition ofsmall
amounts of dilutions of an erythrocyte haemolysate
(haemoglobin content: 136 g/l) to aliquots of a pool of
patients’ specimens.
In-ward assessment
The Seralyzer was placed in the Coronary Care Unit,
Ninewells Hospital and Medical School, for three
months. During this tirne, junior medical staff were
encouraged to collect specimens from patients, centrifuge
these and analyse them in duplicate along with a quality
control material supplied by the laboratory. Analysis of
the specimens was then done by the laboratory in
duplicate using the comparative method. The instrument
was calibrated by a member of the laboratory staff and
the recommendations made regarding tests outside the
laboratory 11 were adhered to as far as possible. Three
members of the junior medical staff participated in the
study, each for a period of one month.
The imprecisions calculated from the analyses of quality
control material and from duplicate analyses of patients’
samples, and the correlations of the in-ward and compa-
rative method results, are shown in table 3 for each of the
three participants. Doctors A and B analysed all speci-
mens in duplicate on a single dilution of serum, whereas
doctor C analysed 12 specimens by preparing two
separate dilutions of serum, and 13 specimens using a
single dilution of each; the performance achieved by the
two techniques was not statistically significantly differ-
ent. The relationship between the pooled results from theL. M. Nelson et al. Evaluation of cholesterol assays
Table 3. Performance characteristics achievedfor in-ward analyses.
Quality control material Patients’ specimens Regression analysis
Mean SD
Junior doctor N (mmol/1) (mmol/l) CV(%) N
Mean SD
(mmol/l) (mmol/l) CV(%) r Slope Intercept
A 7 10.0 0.58 5.8 12
B 16 9.7 0.57 5.9 13
C 8 9.8 0.51 5.3 25
5.9 0"32 5.5 0.67 0’79 +0.92
6"1 0"24 4"0 0.63 0.72 + 1.15
6.3 0.32 5.1 0.89 1.28 -2"23
Overall 31 9"8 0"57 5"8 50 6"1 0"30 4"9 0.79 1"05 -0"80
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Figure 2. Comparison of cholesterol results on 50 patients’
specimens assayed by the Seralyzer operated byjunior medical staff
and by the laboratory.
junior medical staff and the comparative method are
shown in figure 2. Statistical analysis gave a correlation
coefficient of 0.79 and the relationship:
Seralyzer 1"05 comparative method -0’80.
The mean of the results obtained on the Seralyzer was
6"14 mmol/1, which was significantly less than 6"62
mmol/l for the comparative method (p > 0"03: Wilcoxon
matched pairs signed ranks). The performance achieved
by junior medical staff was significantly worse than that
obtained by laboratory both for duplicate analyses of the
50 patient specimens (F-test; p > 0"01), the laboratory
obtaining an SD of 0"09 mmol/1 and a mean of 6"60
mmol/1, and for the analyses ofquality control materials.
Discussion
A previous limited laboratory-based evaluation of the
Seralyzer for, inter alia, cho[esterol assays stated that the
system proved to be simple and easy to use, giving
accurate and precise results [5]: these conclusions were
simply based upon comparison with the method used in
the laboratory of the authors.
Our findings suggest that, since the within-run and
between-run imprecisions are not statistically different,
the instrument is robust under laboratory conditions.
The imprecision is not satisfactory, however, in that the
currently accepted analytical goal for cholesterol analy-
ses, based upon biological variation, is that the CV
should be equal to, or less than, 2.4% 12]. Moreover, the
World Health Organization has laid down criteria for use
of cholesterol analyses in epidemiological studies [13],
and the acceptability criteria ofSD <0" 17 at 2"6 mmol/1,
SD <0" 19 at 5"2 mmol/1, SD <0"21 at 7.8 mmol/1 and SD
0"25 at 10"3 mmol/1 are not fulfilled by the Seralyzer
even under optimal conditions variance. We cannot
envisage that usual methods for improvement of perfor-
mance 14] could lead to the performance characteristics
meeting analytical goals for imprecision.
The correlation between the results obtained with the
Seralyzer and the in-house comparative method was
good, but the results obtained were significantly different.
Moreover, the analyses of materials with assigned values
showed that the Seralyzer gave high results at values
around 6"5 mmol/1. Since the treatment of hypercholes-
terolaemia is based upon comparison of laboratory
results with preset numerical values, we believe that
analyses must, in such circumstances, be without bias
[15]. The WHO criterion [13] is that analytical bias
should not be more than +5.0%; this was not fulfilled at
cholesterol levels of 6" 14 and 6"23 rnmol/1.
The Seralyzer had linearity which was satisfactory since
the published goal is that analyses should be linear up to
10"3 mmol/112. There was insignificant interference from
lipaemia or icterus, but haemolysis caused significant
lowering of result (0"5 mmol/1 per g/1 haemoglobin).
The performance achieved by the junior doctors was
unsatisfactory. Comparison of the imprecision achieved
in the ward for duplicate analyses with that obtained by
the laboratory showed (F-test) that the laboratory was
significantly better. Moreover, the correlations between
the results obtained in the ward and by the comparative
method were poor. These results confirm earlier findings
regarding the use ofboth the Seralyzer by non-laboratory
staff and other analytical equipment used in ward and
clinics 16].
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It is concluded therefore that the Ames Seralyzer is not an
acceptable instrument for performance of cholesterol
assays in either laboratory or ward. Clinical needs of
phlebotomy within 24 h ofadmission, and return ofresult
before patient discharge from coronary care units, must
be fulfilled by adoption of other strategies.
Although the Seralyzer cannot be considered an accept-
able method for cholesterol assays in the laboratory or
ward it is possible that it has a role in identifying patients
requiring follow-up. The laboratory performance in this
study indicated that the accuracy of the results was
acceptable at around 8 mmol/1 although levels around 6
mmol/l were overestimated. The statistical postulates of
Harris suggest that goals for imprecision can perhaps be
less stringent for first line screening [17]. This goal (CV
10%) is fulfilled by .the Seralyzer.
With adequate training, a dedicated nurse in a health
centre might be able to achieve performance equivalent to
that of the laboratory. Patients with cholesterol levels
greater than 7"0 mmol/1, who were thus identified, could
then have their cholesterol level more formally assayed
and treatment, based upon one or preferably two
laboratory derived cholesterol value(s), initiated.
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ANALYTICA 86
3 to 6June 1986 at the Munich Trade Fair Centre
The scientific programme for this international meeting is divided into symposia, posters and the
’Analytica- Forum Mfinchen’ (in this latter sector, exhibiting companies will present papers on developments
in industrial research). Topics to be covered include:
Separation methods
Chromatographic methods, especially TLC/HPTLC, GC, LC/HPLC
Electrophoretic methods
Combined methods: MS-MS, HPLC-MS, GC-MS, GC-IR, LC-MS, LC-NMR, FT-GC, GC-FTIR
Emission spectroscopy
Bioluminescence, chemiluminescence, fluorimetry
NMR, its application in vivo
Radiochemical procedures
Topochemical procedures
Enzymatic analysis
Cell and organ culture based analysis
Dry support reagents including stick tests
Progress in development of reference methods.
Enquiries about the commercial exhibition and registration to Mfinchener Messe- und Ausstellungsgesellschaft mbH, Analytica 86,
Postfach 12 10 09, D 8000 Mnchen 12, FR Germany. Information about scientific contributions from Professor Dr H.
Feldmann, Inst. fftr Physiologische Chemic der Universititt, Goethestrasse 33, D 8000 Mnchen 2, FR Germany.
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